SRO pre-launch investment costs weighing on margins
First two years post-April 2028 SRO launch will be primarily investment/buildout phase with minimal revenue contribution. Management acknowledged significant cost increases in second half of FY27.
ZYDUSLIFE / bear-case history
Track the concerns that keep returning.
Zydus Lifesciences · risk themes across the available quarters.
Research layer active
Bear-case history
Risks carried through the record.
medium
Gross margin compression from Mirabegron settlement costs
MiraBon settlement-related royalty costs impacted Q1 gross margins QoQ; amortization from licensing arrangement continues through Q2 FY28. Analyst Surya asked about sustainability of margin recovery.
Operating cost increase rate vs. revenue growth
Niha raised concerns about sharp QoQ increase in other expenses (~80% driven by acquisitions). Management attributed current run-rate to ongoing Associo integration costs.
Saroglitazar China reimbursement timeline uncertain
China market entry for Saroglitazar requires NRDL reimbursement listing; management declined to quantify steady-state sales potential, citing 2-3 quarters before providing clarity on access timeline.
Miraaben patent litigation outcome
The trial for Miraaben commenced on February 9, 2026, with jury selection completed. Management declined to comment on maximum risk exposure or potential exclusivity duration. A negative outcome could significantly impact US specialty revenue trajectory.
Margin dilution from recent acquisitions
Consumer wellness (Comfort Click) and medical devices (Amplitude Surgical) have lower margins than the base business. With full consolidation, blended margins face structural compression. Management guided 23%+ for Q4 but declined to provide FY27 margin guidance.
Biosimilar Ranibizumab market reentry risk
Sandoz held ~48% market share in Ranibizumab before withdrawing. Management attributed this to commercial rather than regulatory reasons. The attractiveness of reentering with Formicon-partnered biosimilar remains unclear, with launch planned for H2 FY27.
Palosf (paloboflof) pediatric exclusion uncertainty
Management confirmed filing timeline depends on whether pediatric exclusion is granted. If excluded, the opportunity shifts from FY27 to FY28, affecting near-term specialty revenue expectations.